Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Background and Environment Affect Phenotype02:27

Background and Environment Affect Phenotype

Although the genetic makeup of an organism plays a major role in determining the phenotype, there are also several environmental factors, such as temperature, oxygen availability, presence of mutagens, that can alter an organism’s phenotype.
An example of how genetic background affects phenotype can be seen in horses. The Extension gene in horses is responsible for their coat color. A wild-type gene (EE) produces black pigment in the coat, while a mutant gene (ee) produces red pigment. A...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Size-Resolved Lipoprotein Fatty Acid Content as a Novel Nuclear Magnetic Resonance-Derived Trait Specifically Associates with Genetic Variants That Control Fatty Acid Metabolism.

Journal of proteome research·2026
Same author

Toward Precision Cardiac Rehabilitation: Current Limitations and Future Opportunities of Omics and Artificial Intelligence.

Sports medicine (Auckland, N.Z.)·2026
Same author

Emerging Quantitative Targeted Metabolomics Approaches for Future Inborn Errors of Metabolism Screening.

Diagnostics (Basel, Switzerland)·2026
Same author

A Multi-Omics Approach Uncovers Divergent Mechanisms of Asthma in Normal Weight and Obese Children.

Metabolites·2026
Same author

Metabolomic Signature of Visceral Adiposity: Insights from a Population-Based Cohort.

Metabolites·2026
Same author

Clinical, toxicological and pharmacokinetic data of emerging drugs for the treatment of atherosclerosis: are they promising?

Expert opinion on drug metabolism & toxicology·2026

Related Experiment Videos

Metformin Treatment Potentially Modifies Genetically Driven Metabolite-HbA1c Associations: A Gene-Environment

Najeha Anwardeen1, Aleem Razzaq1, Asma A Elashi1

  • 1Biomedical Research Center, QU Health, Qatar University, Doha P.O. Box 2713, Qatar.

Pharmaceuticals (Basel, Switzerland)
|May 27, 2026
PubMed
Summary

Metformin response in type 2 diabetes varies due to genetics and metabolism. This study reveals metformin alters genetically influenced metabolite-HbA1c links, uncovering treatment-dependent effects for personalized diabetes management.

Keywords:
mendelian randomizationmetabolomicsmetforminprecision medicine

Related Experiment Videos

Area of Science:

  • Metabolomics
  • Genetics
  • Pharmacogenomics
  • Type 2 Diabetes Research

Background:

  • Metformin is a primary treatment for type 2 diabetes (T2D), but patient responses vary significantly.
  • This variability suggests that genetic and metabolic factors influence metformin's efficacy beyond drug dosage.

Purpose of the Study:

  • To investigate if genetically influenced associations between metabolites and HbA1c differ based on metformin use.
  • To identify specific metabolites and genetic factors that mediate metformin's variable effects in T2D patients.

Main Methods:

  • Employed Gene-Environment interaction Mendelian Randomization (MR-G×E) in a cohort of 2743 individuals.
  • Developed metabolite-specific polygenic risk scores (PRSs) and used them as genetic instruments to test for PRS-metformin interactions on HbA1c.
  • Adjusted for key covariates including age, sex, BMI, and genetic ancestry.

Main Results:

  • Metformin use significantly altered genetically influenced associations for 18 metabolites with HbA1c.
  • Observed attenuation, strengthening, or reversal of baseline genetic associations under metformin treatment.
  • Identified specific amino acid, sphingomyelin, and carbohydrate metabolites showing altered associations, with some metabolites showing effects only in the presence of metformin.

Conclusions:

  • Metformin modifies genetically influenced metabolite-HbA1c relationships, demonstrating treatment-dependent metabolic effects.
  • Standard Mendelian Randomization approaches may miss these context-specific associations.
  • Findings offer insights into variable metformin response and support precision medicine strategies for T2D.